A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2001
11/28/2001	CN1324240A Treatment of disorders of the outer retina
11/28/2001	CN1324233A Controlled-release pharmaceutical formulations contg. a CGMP PDE-5 inhibitor
11/28/2001	CN1324212A Method for treating or preventing viral infections and associated diseases
11/28/2001	CN1075387C Antitumor agent potentiator comprising IL-6 antagonist
11/28/2001	CN1075375C Compounds with progesterone-antagonistic and anti-oestrogen properties intended from combined use in female contraception
11/27/2001	US6323242 Treatment of disorders secondary to organic impairments
11/27/2001	US6323241 Prostaglandin compositions and methods of treatment for male erectile dysfunction
11/27/2001	US6323234 Methods to treat gastrointestinal lesions and to reduce drug-induced gastrointestinal or renal toxicity
11/27/2001	US6323233 Diindole compounds as antiinflammatory agents
11/27/2001	US6323232 Combination therapy for osteoporosis
11/27/2001	US6323226 Preventing congestive heart failure with cyclooxygenase enzyme
11/27/2001	US6323225 Pharmaceutical composition
11/27/2001	US6323218 Treatment of alzheimer*s disease with metal chelates for amyloidosis
11/27/2001	US6323211 Alpha.-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo
11/27/2001	US6323198 Cognition activators for gamma-aminobutyric acid binding receptors
11/27/2001	US6323191 Generation of chloride secretion from epithelial cells
11/27/2001	US6323188 Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
11/27/2001	US6323175 Composition comprising physiologically compatible liposome, hemoglobin encapsulated in liposome, and nitroxide encapsulated in liposome
11/27/2001	US6322976 Compositions and methods of disease diagnosis and therapy
11/27/2001	US6322826 High protein
11/27/2001	US6322797 Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same
11/27/2001	US6322791 Haemopoietic growth factor antagonists and uses therefor
11/27/2001	US6322784 Glucocorticoid, a compound which stimulates camp production and compound which upregulates peroxisome proliferator activated receptor .gamma. expression
11/27/2001	US6322770 Indazole vitronectin receptor antagonist pharmaceuticals
11/27/2001	US6322493 Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds
11/27/2001	CA2021912C Erythropoietin (epo) peptides and antibodies directed against these
11/22/2001	WO2001088533A2 Lipid uptake assays
11/22/2001	WO2001088532A2 Improved assay techniques using nematode worms
11/22/2001	WO2001088148A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/22/2001	WO2001088136A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/22/2001	WO2001088125A1 MUTATION IN THE β2 NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT ASSOCIATED WITH NOCTURNAL FRONTAL LOBE EPILEPSY
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001088106A2 Novel deoxyribonucleside kinase enzyme multi-substrate variants
11/22/2001	WO2001088104A2 Neural progenitor cell populations
11/22/2001	WO2001088102A1 Method for preventing allograft rejection
11/22/2001	WO2001088097A1 Immune potentiating compositions
11/22/2001	WO2001087981A2 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
11/22/2001	WO2001087980A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/22/2001	WO2001087979A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087977A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087934A2 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
11/22/2001	WO2001087923A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	WO2001087913A2 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	WO2001087887A2 Neuroprotective and anti-proliferative compounds
11/22/2001	WO2001087854A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	WO2001087840A1 Propanoic acid derivatives as integrin receptor antagonists
11/22/2001	WO2001087836A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
11/22/2001	WO2001087835A1 Α crystalline form of perindopril tert-butylamine salt
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087375A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087372A1 Drug combinations useful for prevention of restenosis
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087335A2 Method for selectively inhibiting ghrelin action
11/22/2001	WO2001087334A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087313A1 Combination chemotherapy
11/22/2001	WO2001087307A2 Compositions and methods for the treatment of cancer
11/22/2001	WO2001087304A1 Ophthalmic solution
11/22/2001	WO2001087301A1 Methods for treatment of inflammatory diseases
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087288A2 Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087285A2 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087281A2 Method for enhancing cognitive function
11/22/2001	WO2001087276A1 Hydrogel composition for transdermal drug delivery
11/22/2001	WO2001087272A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087229A2 Treating infections
11/22/2001	WO2001047559A9 Patches for external use
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001036977A3 Identification of disease markers involving mass-based-separation
11/22/2001	WO2001036462A3 Protein c derivatives
11/22/2001	WO2001035995A3 Tr3-specific binding agents and methods for their use
11/22/2001	WO2001034805A3 Human vanilloid receptor gene
11/22/2001	WO2001034128A3 Admixture for intravenous administration of linezolid and other antibacterial agents
11/22/2001	WO2001034126A3 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
11/22/2001	WO2001034119A3 Inhibitors of crystallization in a solid dispersion
11/22/2001	WO2001034093A3 Potentiation of prodrug efficacy
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001028578A3 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
11/22/2001	WO2001027146A3 Chemokine receptor
11/22/2001	WO2001017211A3 Communications system
11/22/2001	WO2001015679A3 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
11/22/2001	WO2000066165A8 Contraceptive compositions containing quinazolinone and benzoxazine derivatives
11/22/2001	WO2000059542A9 Method for a programmed controlled ovarian stimulation protocol
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044616 Surgical irrigation solution and method for inhibition of pain and inflammation
11/22/2001	US20010044473 Treating Parkinson's disease, attention deficit hyperactivity disorder, dementia, depression, schizophrenia and dysautonomia; monoamine oxidase B inhibitor
11/22/2001	US20010044465 Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044456 Non-systemic control of parasites
11/22/2001	US20010044455 Method of treatment for decreasing mortality resulting from congestive heat failure

1 ... 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 ... 1151